



**Final Appraisal Recommendation**

Advice No: 2217 – October 2017

**5-aminolaevulinic acid (Ameluz<sup>®</sup>) 78 mg/g gel**

**Submission by Biofrontera**

**Recommendation of AWMSG**

**5-aminolaevulinic acid (Ameluz<sup>®</sup>) is recommended as an option for use within NHS Wales for the treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults.**

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3372), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 2217:  
5-aminolaevulinic acid (Ameluz<sup>®</sup>) 78 mg/g gel. October 2017.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).